Vimarsana
Biggest News Aggregation in the World

Alfasigma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alfasigma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alfasigma Today - Breaking & Trending Today

Galapagos Agrees To Sell Jyseleca To Alfasigma - Vimarsana News

Galapagos Agrees To Sell Jyseleca To Alfasigma

Galapagos NV (GLPG), a bio-pharmaceutical company, Tuesday said it entered into a deal to sell its Jyseleca business to Italian pharma company Alfasigma. As per the terms of the agreement, Michele Manto the Chief Commercial Officer of the company has resigned and will be joining Alfasigma in the same capacity.

Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc. - Vimarsana News

Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.

BOLOGNA, Italy, November 08, 2023--Alfasigma S.p.A. ("Alfasigma") announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. ("Interstellar"), successfully completed its tender offer to purchase all outstanding shares of common stock of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) ("Intercept"), at a price of USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes.

Source: yahoo.com
Alfasigma S.p.A. Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Pending Acquisition of Intercept Pharmaceuticals, Inc. - Vimarsana News

Alfasigma S.p.A. Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Pending Acquisition of Intercept Pharmaceuticals, Inc.

BOLOGNA, Italy, October 26, 2023--Alfasigma S.p.A. ("Alfasigma") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") with respect to Alfasigma’s proposed acquisition of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) ("Intercept") expired at 11:59 p.m. on October 25, 2023. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the tender offer. Other customary offer conditions remain to

Source: yahoo.com
ICPT Alert: Monsey Firm of Wohl & Fruchter Investigating - Vimarsana News

ICPT Alert: Monsey Firm of Wohl & Fruchter Investigating

MONSEY, N.Y., Sept. 26, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Intercept...

After NASH Hopes Are Dashed, Intercept Pharma Agrees to $794M Buyout - Vimarsana News

After NASH Hopes Are Dashed, Intercept Pharma Agrees to $794M Buyout

Intercept Pharmaceuticals’ acquisition by Alfasigma comes three months after the FDA again rejected the biotech’s drug as a treatment for the fatty liver disease NASH. But Intercept still has rare liver disease assets, and Italy-based Alfasigma says acquiring the company will help it expand in gastroenterology and hepatology.